Large-scale rare variant burden testing in Parkinson's disease.

Area of Science:

• Genetics
• Neuroscience
• Genomics

Background:

• Parkinson's disease (PD) has a significant heritable component, with over 90 common variants identified.
• Previous research has focused on common variants, leaving a gap in large-scale rare variant analysis for PD.

Purpose of the Study:

• To investigate the rare genetic component of Parkinson's disease using whole genome and whole exome sequencing data.
• To identify novel genes and pathways associated with Parkinson's disease risk through rare variant analysis.

Main Methods:

• Utilized whole genome and whole exome sequencing data from over 58,000 individuals (7184 PD cases, 6701 proxy cases, 51,650 controls).
• Conducted meta-analyses of burden tests on small indels and protein-altering single nucleotide variants, prioritizing functional impact.
• Employed data from the Accelerating Medicines Partnership Parkinson's disease (AMP-PD) initiative, NIH, UK Biobank, and Genentech.

Main Results:

• Identified several genes reaching exome-wide significance, including previously implicated GBA1 and LRRK2.
• Observed potential novel risk associations in genes such as B3GNT3, AUNIP, ADH5, TUBA1B, OR1G1, CAPN10, and TREML1.
• Found that B3GNT3 and TREML1 variants may suggest a role for neuroinflammation in Parkinson's disease.

Conclusions:

• This is the largest analysis to date of rare genetic variants in Parkinson's disease.
• Confirms the role of GBA1 and LRRK2 in PD pathogenesis and suggests potential new avenues for research, including neuroinflammation.
• Highlights the importance of rare variant analysis in uncovering the genetic architecture of Parkinson's disease.